Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice

Gheybi, Elaheh and Salmanian, Ali Hatef and Imani Fooladi, Abbas Ali and Salimian, Jafar and Mahmoodzadeh Hosseini, Hamideh and Halabian, Raheleh and Amani, Jafar (2018) Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice. Iranian Journal of Basic Medical Sciences, 21 (1). pp. 26-32.

[img]
Preview
Text
IJBMS_Volume 21_Issue 1_Pages 26-32.pdf

Download (1MB) | Preview
Official URL: http://ijbms.mums.ac.ir/article_9919.html

Abstract

Objective(s): Breast cancer is one of the most common cancers in the world and is on the increase. MUC1 and HER2 as tumor-associated antigens (TAAs) are abnormally expressed to some extent in 75–80 of breast cancers. In our present research, a novel chimeric MUC1-HER2 (HM) protein was designed and used to study whether an immune response can be generated against these TAAs. In vitro analysis of the HER2-MUC1 construct confirmed the co-expression of MUC1 and HER2. Materials and Methods: BALB/c mice were immunized with this novel chimeric protein. The humoral immune response was assessed by enzyme-linked immunosorbent assay (ELISA). Then, BALB/c mice were injected subcutaneously 2×105 4T1-MUC1-HER2 tumor cells. Subsequently, tumor size and tumor necrosis measurements, MTT, cytokines assay and survival test were performed. Results: The results implied a critical role of HER2 and MUC1 antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer. Conclusion: The results implied a critical role of HER2 and MUC1 antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer.

Item Type: Article
Subjects: QW Microbiology and Immunology
Divisions: Journals > Iranian J Basic Medical Sciences
Depositing User: ijbms ijbms
Date Deposited: 24 Dec 2017 16:32
Last Modified: 24 Dec 2017 16:32
URI: http://eprints.mums.ac.ir/id/eprint/8819

Actions (login required)

View Item View Item